Ocugen (OCGN) Cash from Investing Activities (2014 - 2026)
Ocugen (OCGN) posted Cash from Investing Activities of -$6000.0 for Q1 2026, up 82.86% on a QoQ basis from -$35000.0 in Q4 2025, and up 94.12% year-over-year from -$3090.9 in Q1 2025.
Ocugen (OCGN) Cash from Investing Activities (2014 - 2026) Analysis & Trends
Ocugen's Cash from Investing Activities history runs 13 years deep, the most recent figure standing at -$6000.0 for Q1 2026.
- Quarterly Cash from Investing Activities rose 94.12% year-over-year to -$6000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$215000.0 (up 81.06% YoY) and the FY2025 annual result came in at -$311000.0, up 90.81% from the prior year.
- Cash from Investing Activities was -$6000.0 for Q1 2026 at Ocugen, up from -$35000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $5.7 million in Q2 2023 and bottomed at -$15.3 million in Q4 2022.
- A 5-year average of -$1.0 million and a median of -$102000.0 in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 7866.15% — and 2023, when it surged 1643.05%.
- Ocugen's Cash from Investing Activities stood at -$15.3 million in 2022, then jumped by 82.2% to -$2.7 million in 2023, then soared by 99.52% to -$13000.0 in 2024, then sank by 169.23% to -$35000.0 in 2025, then jumped by 82.86% to -$6000.0 in 2026.
- Business Quant data shows OCGN's Cash from Investing Activities at -$6000.0 in Q1 2026, -$35000.0 in Q4 2025, and -$86000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Ocugen | 415.98 Mn | 415.98 Mn | - | -6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,000.00 |
| Mar 31, 2026 | -6,000.00 |
| Dec 31, 2025 | -35,000.00 |
| Dec 31, 2025 | -35,000.00 |
| Sep 30, 2025 | -86,000.00 |
| Sep 30, 2025 | -86,000.00 |
| Jun 30, 2025 | -88,000.00 |
| Jun 30, 2025 | -88,000.00 |
| Mar 31, 2025 | -102,000.00 |
| Mar 31, 2025 | -102,000.00 |
| Dec 31, 2024 | -13,000.00 |
| Dec 31, 2024 | -13,000.00 |
| Sep 30, 2024 | -507,000.00 |
| Sep 30, 2024 | -507,000.00 |
| Jun 30, 2024 | -513,000.00 |
| Jun 30, 2024 | -513,000.00 |
| Mar 31, 2024 | -2.35 Mn |
| Mar 31, 2024 | -2.35 Mn |
| Dec 31, 2023 | -2.72 Mn |
| Dec 31, 2023 | -2.72 Mn |